Small Molecules
19 September 2016
Teva Announces Results from Exploratory 52-Week Phase 2 PRIDE-HD Study of Pridopidine in Huntington Disease19 September 2016
FDA approves new five-year-contraceptive of Bayer17 September 2016
Nuevolution: Presentation of Preclinical Data on its BET BD1 Program at Discovery on Target 201617 September 2016
Novartis BAF312 reduced the risk of disability progression in pivotal phase III study in secondary progressive MS patients17 September 2016
Retrotope Announces Phase I/II Clinical Trial Results of RT001 in Treatment of Friedreich’s Ataxia17 September 2016
Glyxambi® (empagliflozin/linagliptin) approval recommended by CHMP for adults with type 2 diabetes in the European Union17 September 2016
Oral Ozanimod Efficacy and Safety Results at 2 Years from Phase 2 RADIANCE Trial of Patients with Relapsing Multiple Sclerosis Presented at 32nd ECTRIMS16 September 2016
Interim results from Trek Therapeutics’ Phase 2 study show triple combination therapy achieves 100% SVR4 in genotype 4 HCV patients15 September 2016
Epizyme Earns $6 Million Milestone Payment from GlaxoSmithKline for Initiation of Clinical Development with First-in-Class PRMT5 Inhibitor15 September 2016
Cara Therapeutics Initiates Enrollment in Phase 2b Trial of Peripherally Acting Kappa Opioid Agonist, Oral CR845, in Chronic Pain Patients15 September 2016
Calithera Announces First Patient Dosed in a Phase I Study of CB-1158, the First-in-Class Inhibitor of the Immuno-Oncology Target Arginase15 September 2016
Azevan Pharmaceuticals Reports Positive Phase 2 Exploratory Clinical Study Results with SRX246 in Intermittent Explosive Disorder15 September 2016
Cumberland Pharmaceuticals Announces New Program To Develop Portaban™ For Portal Hypertension15 September 2016
Aerie Pharmaceuticals Reports Positive Roclatan™ (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% Phase 3 Topline Efficacy Results15 September 2016
Poxel Presents New Data on Imeglimin and PXL770 at the European Association for the Study of Diabetes Annual Meeting15 September 2016
Eisai receives license for new indication for anticancer agent Kisplyx (lenvatinib mesylate) for treatment of advanced renal cell carcinoma15 September 2016
FDA Advisory Committee Votes that Qapzola(TM) (apaziquone) Has Not Shown Substantial Evidence of a Treatment Effect Over Placebo14 September 2016
GlycoMimetics Doses First Patient in Phase 1 Clinical Trial of Drug Candidate GMI-1271 for Multiple MyelomaNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
SubscribeNewsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
SubscribeFeatured reports